CervoMed Inc.
CRVO Nasdaq· Pharmaceutical Preparations
Last close · Oct 23, 2026
$2.31
KIRA · Stoqly’s AI analyst, in plain words
- CervoMed Inc. had $4.0M of revenue in fiscal 2025, down 58.9% on the year before.
- Its operating margin was −706.2%, down 519.0 pts: of every 100 in sales, about −706 is left after running the business.
- CervoMed Inc. lost $27.0M in fiscal 2025.
Market cap
—
P/E
—
Revenue
$4.0M
Net income
−$27.0M
Free cash flow
—
Operating margin
−706.2%
CervoMed Inc. in 30 seconds · fiscal 2025
Are sales growing?
−58.9%
No. Sales fell 58.9% last year.
Does it make a profit?
−673.1%
No. It lost money last year.
What CervoMed Inc. does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K · Mar 13, 2026
- Legal name
- CervoMed Inc.
- CIK
- 0001053691
CervoMed Inc. · CRVO
Results and finances
The last 5 fiscal years. Amounts in USD.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Revenue | — | $0.0M | $7.1M | $9.7M | $4.0M |
| Revenue growth | — | — | — | 36.3% | −58.9% |
| Operating margin | — | — | −109.3% | −187.2% | −706.2% |
| Net income | −$24.1M | −$5.8M | −$2.2M | −$16.3M | −$27.0M |
| Net margin | — | — | −30.4% | −167.3% | −673.1% |
| Diluted EPS | $1,946,859.00 | $2,038,891.00 | — | — | — |
| Cash | |||||
| Cash from operations | −$14.5M | −$2.6M | −$7.4M | −$16.5M | −$23.5M |
| Debt and strength | |||||
| Cash and short-term investments | $37.3M | $16.5M | $7.8M | $38.9M | $20.9M |
| Shareholders' equity | $34.9M | −$33.3M | $7.4M | $39.2M | $18.2M |
| Current ratio | 12.9x | — | — | 11.1x | 4.9x |
| Interest coverage | — | −5,792.5x | — | — | — |
| Returns and quality | |||||
| Return on equity | −80.7% | −713.6% | — | −69.9% | −93.9% |
| Return on tangible equity | −69.0% | — | −29.4% | −41.6% | −148.0% |
| Altman Z'' | 3.0 | — | — | 8.4 | −12.9 |
Insiders bought, 12 months
$3.5M
4 insiders
Insiders sold, 12 months
$0.0M
0 insiders
Of sales under plans
—
$0.0M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
CervoMed Inc. · CRVO
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $2.31 a share, the company is worth —.
Source: SEC EDGAR XBRL filings (CIK 0001053691). Data updated October 24, 2026. For information only — not investment advice. Check the original filings before relying on any figure.